Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341655 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBALDH1A1HTTMAPT | |
| SCHEMBL2537515 | 0.79 | ALDH1A1 (0.71) | SMN1; SMN2POLBALDH1A1HTTMAPT | |
| SCHEMBL659064 | 0.78 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1MAPTMAPK1RAB9A | |
| SCHEMBL8970607 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBALDH1A1HTTMAPT | |
| SCHEMBL2537514 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBALDH1A1HTTMAPT | |
| SCHEMBL15504635 | 0.76 | MAPT (0.57) | SMN1; SMN2POLBALDH1A1HTTMAPT | |
| SCHEMBL12266129 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBALDH1A1HTTMAPT | |
| Hydrochloric Acid SCHEMBL29005233 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1MAPTMAPK1RAB9A | |
| SCHEMBL27760232 | 0.75 | KDM4E (0.55) | SMN1; SMN2ALDH1A1HTTLMNARAB9A | |
| SCHEMBL3832407 | 0.74 | ALDH1A1 (0.77) | SMN1; SMN2POLBALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| EP-2303890-A2 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | Progenics Pharmaceuticals, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009155527-A9 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009155527-A2 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PIK3CA, AKT1, PIK3R5 | SMN1; SMN2 1839/4885POLB 2074/4885ALDH1A1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.